Navigation Links
KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
Date:8/28/2007

Technology to be Applied to Both Clinical- and Preclinical-Stage Compounds

in Merck KGaA Pipeline

EMERYVILLE, Calif., Aug. 28 /PRNewswire/ -- KineMed, Inc., a pathway-based drug discovery and development company, announced today that it will collaborate with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to discover new applications for drug candidates. KineMed's proprietary pathway-based drug discovery and development technology identifies compounds that can modulate key metabolic pathways present in both preclinical animal models and in humans. By measuring real-time activity of drugs against these targeted pathways, KineMed's technology reduces development risk by selecting drug candidates with the best potential to demonstrate clinical efficacy and confirm desired drug activity in first-in-man studies.

In the collaboration, KineMed will identify new therapeutic utility in in vivo preclinical models by applying its proprietary translational medicine technologies. Once a disease target is established for a selected drug candidate, KineMed and Merck KGaA will jointly determine the best development and commercialization path for the development candidates being studied.

Under the terms of the agreement, KineMed will receive from Merck an upfront payment, milestones and royalty payments on products advanced with KineMed's technology. Additional terms of the deal were not disclosed.

David Fineman, President and CEO of KineMed, commented, "We are pleased to expand our relationship with Merck KGaA into this broader development collaboration. Our technology uniquely enables our partners to screen development candidates against KineMed's dynamic targets of pathway kinetics. Partnering with KineMed further enables its partners to rapidly demonstrate on-mechanism dose response in first-in-man studies with KineMed's unique translational medicine capabilities."

Mr. Fineman continued, "In this collaboration with Merck, KineMed will be using its technology to identify new therapeutic activities of pipeline compounds. The collaboration preserves KineMed's freedom to operate on its own development programs as well as partner with other companies in key disease indications."

About KineMed, Inc.

KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag(TM) and KineMarker(TM)) to both identify active drug candidates preclinically and confirm their therapeutic activity and dose response in first-in-man studies. KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration.

KineMed is working to develop drugs both on its own and with pharmaceutical collaborators in therapeutic focus areas where it can demonstrate functional modulation of specific biological pathways that mediate disease. The Company has multiple development programs with more than a dozen major pharmaceutical companies, including Bayer, Merck, Merck KGaA, Organon and Roche.

For further information about KineMed, please visit: http://www.kinemed.com/


'/>"/>
SOURCE KineMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GE, St. Jude to collaborate on visualization technology
2. GE Healthcare, MobileAccess to collaborate on hospital wireless
3. GE Healthcare, Harvard medical school to collaborate on nervous system research
4. Madison, Milwaukee med schools to collaborate on tech transfer
5. EraGen collaborates with Emory University on HIV detection system
6. Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression Vector
7. Silencer Validated siRNAs
8. Using Validated siRNAs in Functional Genomic Assays
9. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
10. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
11. Stem cell bank announcement validates quality of Wisconsin research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  BD (Becton, Dickinson ... medical technology company, today announced the launch of the ... Biology and Technology (AGBT) Meeting. ... enables genomic research by providing cost effective NGS library ... is a high-throughput, fully integrated, next generation sequencing (NGS) ...
(Date:2/11/2016)... , February 11, 2016 Non-profit ... Promote Genetic Understanding to Support Research and Discovery ... 100K, today announced an ambitious plan to sequence 100,000 individuals. ... Asian countries and at least 7 of North and East ... In the first phase, the project will focus on creating ...
(Date:2/11/2016)... HILDEN , Germany and ... QGEN ; Frankfurt Prime Standard: ... new QIAseq Targeted RNA Panels for gene expression profiling, ... next-generation sequencing (NGS). The panels enable researchers to select ... expression fold changes and discover interactions between genes, cellular ...
(Date:2/11/2016)... -- Wellcentive today announced it has been selected by FamilyCare ... community care organization (CCO) with more than 130,000 ... and care management solutions and services. Wellcentive,s capabilities ... managers, analysts and care managers while providing insight ... members. Oregon . ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:1/27/2016)... WEST CHESTER, Ohio , Jan. 27, 2016 /PRNewswire/ ... services supplier based in West Chester, Ohio ... and their award winning service staff, based in ... Track,s technical capacity and ability to provide modifications, installations ... John Dovalina , CEO of PLUS, commented, "PLUS ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):